Theresa A. Guise, M.D.

Peer-Reviewed Articles

1. Pagnotti GM, Thompson WR, Guise,TA, Rubin CT. Suppression of Cancer-associated bone loss through dynamic mechanical loading. Bone 150:115998, 2021. e-Pub 2021. PMID: 33971314.
2. Brown JE, Wood SL, Confavreux C, Abe M, Weilbaecher K, Hadji P, Johnson RW, Rhoades JA, Edwards CM, Croucher PI, Juarez P, El Badri S, Ariaspinilla G, D'Oronzo S, Guise TA, Van Poznak C. Management of bone metastasis and cancer treatment-induced bone loss during the COVID-19 pandemic: An international perspective and recommendations. J Bone Oncol 29:100375, 2021. e-Pub 2021. PMID: 34131559.
3. Nagata Y, Miyagawa K, Ohata Y, Petrusca DN, Pagnotti GM, Mohammad KS, Guise TA, Windle JJ, David Roodman G, Kurihara N. Increased S1P expression in osteoclasts enhances bone formation in an animal model of Paget's disease. J Cell Biochem 122(3-4):335-348, 2021. e-Pub 2020. PMID: 33107091.
4. Patterson AM, Wu T, Chua HL, Sampson CH, Fisher A, Singh P, Guise TA, Feng H, Muldoon J, Wright L, Plett PA, Pelus LM, Orschell CM. Optimizing and Profiling Prostaglandin E2 as a Medical Countermeasure for the Hematopoietic Acute Radiation Syndrome. Radiat Res 195(2):115-127, 2021. PMID: 33302300.
5. Handley NR, Feng FY, Guise TA, D'Andrea D, Kelly WK, Gomella LG. Preserving Well-being in Patients With Advanced and Late Prostate Cancer. Urology. e-Pub 2020. PMID: 33373704.
6. Yi X, Wright LE, Pagnotti GM, Uzer G, Powell KM, Wallace JM, Sankar U, Rubin CT, Mohammad K, Guise TA, Thompson WR. Mechanical suppression of breast cancer cell invasion and paracrine signaling to osteoclasts requires nucleo-cytoskeletal connectivity. Bone Res 8(1):40, 2020. e-Pub 2020. PMID: 33298883.
7. Xu W, Yang Y, Hu Z, Head M, Mangold KA, Sullivan M, Wang CH, Saha P, Gulukota K, Helseth DL Jr, Guise T, Prabhakar BS, Kaul K, Schreiber H, Seth P. LyP-1-modified oncolytic adenoviruses targeting transforming growth factor β inhibit tumor growth and metastases and augment immune checkpoint inhibitor therapy in breast cancer mouse models. Hum Gene Ther 31(15-16):863-880, 2020. PMID: 32394753.
8. Morris MJ, Corey E, Guise TA, Gulley JL, Kevin Kelly W, Quinn DI, Scholz A, Sgouros G. Radium-223 mechanism of action: implications for use in treatment combinations. Nat Rev Urol 16(12):745-756, 2019. PMID: 31712765.
9. Pagnotti GM, Styner M, Uzer G, Patel VS, Wright LE, Ness KK, Guise TA, Rubin J, Rubin CT. Combating osteoporosis and obesity with exercise: leveraging cell mechanosensitivity. Nat Rev Endocrinol 15(6):339-355, 2019. PMID: 30814687.
10. Saito H, Gasser A, Bolamperti S, Maeda M, Matthies L, Jähn K, Long CL, Schlüter H, Kwiatkowski M, Saini V, Pajevic PD, Bellido T, van Wijnen AJ, Mohammad KS, Guise TA, Taipaleenmäki H, Hesse E. TG-interacting factor 1 (Tgif1)-deficiency attenuates bone remodeling and blunts the anabolic response to parathyroid hormone. Nat Commun 10(1):1354, 2019. PMID: 30902975.
11. Singh P, Hoggatt J, Kamocka MM, Mohammad KS, Saunders MR, Li H, Speth J, Carlesso N, Guise TA, Pelus LM. Neuropeptide Y regulates a vascular gateway for hematopoietic stem and progenitor cells. J Clin Invest 127(12):4527-4540, 2017. PMID: 29130940.
12. Regan JN, Mikesell C, Reiken S, Xu H, Marks AR, Mohammad KS, Guise TA, Waning DL. Osteolytic Breast Cancer Causes Skeletal Muscle Weakness in an Immunocompetent Syngeneic Mouse Model. Front Endocrinol 19(8):358, 2017. PMID: 29312148.
13. Ross MH, Esser AK, Fox GC, Schmieder AH, Yang X, Hu G, Pan D, Su X, Xu Y, Novack DV, Walsh T, Colditz GA, Lukaszewicz GH, Cordell E, Novack JS, Fitzpatrick JAJ, Waning DL, Mohammad KS, Guise TA, Lanza GM, Weilbaecher KN. Bone-induced expression of integrin β3 enables targeted nanotherapy of breast cancer metastases. Cancer Res 77(22):6299-6312, 2017. PMID: 28855208.
14. Juárez P, Fournier PGJ, Mohammad KS, McKenna RC, Davis HW, Peng XH, Niewolna M, Mauviel A, Chirgwin JM, Guise TA. Halofuginone inhibits TGF-β/BMP signaling and in combination with zoledronic acid enhances inhibition of breast cancer bone metastasis. Oncotarget 8(49):86447-86462, 2017. PMID: 29156807.
15. Trivedi T, Zheng Y, Fournier PGJ, Murthy S, John S, Schillo S, Dunstan CR, Mohammad KS, Zhou H, Seibel MJ, Guise TA. The vitamin D receptor is involved in the regulation of human breast cancer cell growth via a ligand-independent function in cytoplasm. Oncotarget 8(16):26687-26701, 2017. PMID: 28460457.
16. Wright LE, Harhash AA, Kozlow WM, Waning DL, Regan JN, She Y, John SK, Murthy S, Niewolna M, Marks AR, Mohammad KS, Guise TA. Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in vivo. Oncotarget 8(5):8406-8419, 2017. PMID: 28039445.
17. Khan AA, Morrison A, Kendler DL, Rizzoli R, Hanley DA, Felsenberg D, McCauley LK, O'Ryan F, Reid IR, Ruggiero SL, Taguchi A, Tetradis S, Watts NB, Brandi ML, Peters E, Guise T, Eastell R, Cheung AM, Morin SN, Masri B, Cooper C, Morgan SL, Obermayer-Pietsch B, Langdahl BL, Dabagh RA, Davison KS, Sándor GK, Josse RG, Bhandari M, El Rabbany M, Pierroz DD, Sulimani R, Saunders DP, Brown JP, Compston J. International Task Force on Osteonecrosis of the Jaw. Case-Based Review of Osteonecrosis of the Jaw (ONJ) and Application of the International Recommendations for Management From the International Task Force on ONJ. J Clin Densitom 20(1):8-24, 2017. PMID: 27956123.
18. Bonetto A, Kays JK, Parker VA, Matthews RR, Barreto R, Puppa MJ, Kang KS, Carson JA, Guise TA, Mohammad KS, Robling AG, Couch ME, Koniaris LG, Zimmers TAA. Differential Bone Loss in Mouse Models of Colon Cancer Cachexia. Front Physiol 11(7):679, 2017. PMID: 28123369.
19. Zhang P, Xing C, Rhodes SD, He Y, Deng K, Li Z, He F, Zhu C, Nguyen L, Zhou Y, Chen S, Mohammad KS, Guise TA, Abdel-Wahab O, Xu M, Wang QF, Yang FC. Loss of Asxl1 Alters Self-Renewal and Cell Fate of Bone Marrow Stromal Cell, Leading to Bohring-Opitz-like Syndrome in Mice. Stem Cell Reports 6(6):914-925, 2016. PMID: 27237378.
20. Teramachi J, Nagata Y, Mohammad K, Inagaki Y, Ohata Y, Guise T, Michou L,Brown JP, Windle JJ, Kurihara N, Roodman GD. Measles virus nucleocapsid protein increases osteoblast differentiation in Paget's disease. J Clin Invest 126(3):1012-1022, 2016. PMID: 26878170.
21. Edwards BJ, Gradishar WJ, Smith ME, Pacheco JA, Holbrook J, McKoy JM, Nardone B, Tica S, Godinez-Puig V, Rademaker AW, Helenowski IB, Bunta AD, Stern PH, Rosen ST, West DP, Guise TA. Elevated incidence of fractures in women with invasive breast cancer. Osteoporos Int 27(2):499-507, 2016. PMID: 26294292.
22. Yang Y, Xu WW, Neill T, Hu Z, Wang CH, Xiao X, Stock S, Guise T, Yun CO, Brendler CB, Iozzo RV, Seth P. Systemic Delivery of an Oncolytic Adenovirus Expressing Decorin for the Treatment of Breast Cancer Bone Metastases. Hum Gene Ther 26(12):813-825, 2015. PMID: 26467629.
23. Waning DL, Mohammad KS, Reiken S, Xie W, Andersson DC, John S, Chiechi A, Wright LE, Umanskaya A, Niewolna M, Trivedi T, Charkhzarrin S, Khatiwada P, Wronska A, Haynes A, Benassi MS, Witzmann FA, Roodman GD, Marks AR, Guise TA. Excess TGFβ mediates muscle weakness associated with bone metastases in mice. Nature Medicine 21(11):1262-1271, 2015. PMID: 26457758.
24. Rhodes SD, Yang H, Dong R, Menon K, He Y, Li Z, Chen S, Staser KW, Jiang L, Wu X, Yang X, Peng X, Mohammad KS, Guise TA, Xu M, Yang FC. Nf1 Haploinsufficiency Alters Myeloid Lineage Commitment and Function, Leading to Deranged Skeletal Homeostasis. J Bone Miner Res 30(10):1840-1851, 2015. PMID: 25917016.
25. Wright LE, Buijs JT, Kim H-S, Coats LE, Anne M. Scheidler AM, John SK, She Y, Murthy S, Ma N, Chin-Sinex HJ, Bellido TM, Bateman TA, Mendonca MS, Mohammad KS, Guise TA. Single-limb irradiation induces local and systemic bone loss in a murine model. J Bone Miner Res 30(7):1268-1279, 2015. PMID: 25588731.
26. Stayrook K, Mack JK, Cerabona D, Edwards DF, Bui HH, Niewolna M, Fournier PGJ, Mohammad KS, Waning D, Guise TA. TGFβ-Mediated Induction of SphK1 as a Potential Determinant in Human MDA-MB-231 Breast Cancer Cell Bone Metastasis. Bonekey Rep 8(4):719, 2015. PMID: 26157579.
27. Fournier PGJ, Juárez P, Jiang G, Clines GA, Niewolna M, Kim H-S, Walton HW, Peng X, Liu Y, Mohammad KS, Wells CD, Chirgwin JM, Guise TA. The TGFβ Signaling Regulator PMEPA1 Suppresses Prostate Cancer Metastases to Bone. Cancer Cell 27(6):809-821, 2015. PMID: 25982816.
28. Santulli G, Pagano G, Sardu C, Xie W, Reiken S, Luca D'Ascia S, Cannone M, Marziliano N, Trimarco B, Guise TA, Lacampagne A, Marks AR. Calcium release channel RyR2 regulates insulin release and glucose homeostasis. J Clin Invest 125(5):1968-1978, 2015. PMID: 25844899.
29. Buijs JT, Matula KM, Cheung H, Kruithof-de Julio M, van der Mark M, Snoeks TJ, Cohen R, Corver WE, Mohammad KS, Jonkers J, Guise TA, van der Pluijm G. Spontaneous Bone Metastases in a Preclinical Orthotopic Model of Invasive Lobular Carcinoma; the Effect of Pharmacological Targeting TGFβ receptor I kinase. J Pathol 235(5):745-759, 2015. PMID: 25421310.
30. Wu C, Rankin EB, Castellini L, Fernandez-Alcudia J, LaGory EL, Andersen R, Rhodes SD, Wilson TL, Mohammad KS, Castillo AB, Guise TA, Schipani E, Giaccia AJ. Oxygen-sensing PHDs regulate bone homeostasis through the modulation of osteoprotegerin. Genes Dev 29(8):817-831, 2015. PMID: 25846796.
31. Rhodes SD, Zhang W, Yang D, Yang H, Chen S, Wu X, Li X, Yang X, Mohammad KS, Guise TA, Bergner AL, Stevenson DA, Yang FC. Dystrophic spinal deformities in a neurofibromatosis type 1 murine model. PloS ONE 10(3):e0119093, 2015. PMID: 25786243.
32. Khan AA, Morrison A, Hanley DA, Felsenberg D, McCauley LK, O'Ryan F, Reid IR, Ruggiero SL, Taguchi A, Tetradis S, Watts NB, Brandi ML, Peters E, Guise T, Eastell R, Cheung AM, Morin SN, Masri B, Cooper C, Morgan SL, Obermayer-Pietsch B, Langdahl BL, Al Dabagh R, Davison KS, Kendler DL, Sándor GK, Josse RG, Bhandari M, El Rabbany M, Pierroz DD, Sulimani R, Saunders DP, Brown JP, Compston J; International Task Force on Osteonecrosis of the Jaw. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res 30(1):3-23, 2015. PMID: 25414052.
33. Xu W, Zhang Z, Yang Y, Hu Z, Wang CH, Morgan M, Wu Y, Hutten R, Xiao X, Stock S, Guise T, Prabhakar BS, Brendler C, Seth P. Ad5/48 Hexon Oncolytic Virus Expressing sTGFβRIIFc Produces Reduced Hepatic and Systemic Toxicities and Inhibits Prostate Cancer Bone Metastases. Mol Ther 22(8):1504-1517, 2014. PMID: 24791939.
34. Waning DL, Guise TA. Molecular Mechanisms of Bone Metastasis and Associated Muscle Weakness. Clin Cancer Res 20(12):3071-3077, 2014. PMID: 24677373.
35. Rhodes SD, Wu X, He Y, Chen S, Yang H, Staser KW, Wang J, Zhang P, Jiang C, Yokota H, Dong R, Peng X, Yang X, Murthy S, Azhar M, Mohammad KS, Xu M, Guise TA, Yang FC. Hyperactive transforming growth factor-β1 signaling potentiates skeletal defects in a neurofibromatosis type 1 mouse model. J Bone Miner Res 28(12):2476-2489, 2013. PMID: 23703870.
36. Casimiro S, Mohammad KS, Pires R, Tato-Costa J, Alho I, Teixeira R, Carvalho A, Ribeiro S, Lipton A, Guise TA, Costa L. RANKL/RANK/MMP-1 Molecular Triad Contributes to the Metastatic Phenotype of Breast and Prostate Cancer Cells In Vitro. PloS ONE 8(5):e63153, 2013. PMID: 23696795.
37. Wright LE, Frye JB, Lukefahr AL, Timmermann BN, Mohammad KS, Guise TA, Funk JL. Curcuminoids Block TGF-β Signaling in Human Breast Cancer Cells and Limit Osteolysis in a Murine Model of Breast Cancer Bone Metastasis. J Nat Prod 76(3):316-321, 2013. PMID: 23145932.
38. Hoggatt J, Mohammad KM, Singh P, Hoggatt AF, Chitteti BR, Speth JM, Hu P, Poteat BA, Stilger KN, Ferraro F, Silberstein L, Wong FK, Farag SS, Czader M, Milne GL, Breyer RM, Serezani CH, Scadden DT, Guise TA, Srour EF and Pelus LM. Differential Stem and Progenitor Trafficking by Cyclooxygenase/Prostaglandin E2. Nature 495(7441):365-369, 2013. PMID: 23485965.
39. Juárez P, Mohammad KS, Yin JJ, Fournier PG, McKenna RC, Davis HW, Peng XH, Niewolna M, Javelaud D, Chirgwin JM, Mauviel A, Guise TA. Halofuginone inhibits the establishment and progression of melanoma bone metastases. Cancer Res 72(23):6247-6256, 2012. PMID: 23002206.
40. Hadji P, Gnant M, Body JJ, Bundred NJ, Brufsky A, Coleman RE, Guise TA, Lipton A, Aapro MS. Cancer treatment-induced bone loss in premenopausal women: A need for therapeutic intervention?. Cancer Treat Res 38(6):798-806, 2012. PMID: 22429722.
41. Hu Z, Gupta J, Zhang Z, Gerseny H, Berg A, Chen YJ, Zhang Z, Du H, Brendler CB, Xiao X, Pienta KJ, Guise T, Lee C, Stern PH, Stock S, Seth P. Systemic Delivery of Oncolytic Adenoviruses Targeting Transforming Growth Factor-β Inhibits Established Bone Metastasis in a Prostate Cancer Mouse Model. Hum Gene Ther 23(8):871-882, 2012. PMID: 22551458.
42. Cao L, Shao M, Schilder J, Guise T, Mohammad KS, Matei D. Tissue transglutaminase links TGF-β, epithelial to mesenchymal transition and a stem cell phenotype in ovarian cancer. Oncogene 31(20):2521-2534, 2012. PMID: 21963846.
43. Pollari S, Käkönen RS, Mohammad KS, Rissanen JP, Halleen JM, Wärri A, Nissinen L, Pihlavisto M, Marjamäki A, Perälä M, Guise TA, Kallioniemi O, Käkönen SM. Heparin-like polysaccharides reduce osteolytic bone destruction and tumor growth in a mouse model of breast cancer bone metastasis. Mol Cancer Res 10(5):597-604, 2012. PMID: 22522458.
44. Nickerson NK, Mohammad KS, Gilmore JL, Crismore E, Bruzzaniti A, Guise TA, Foley J. Decreased Autocrine EGFR Signaling in Metastatic Breast Cancer Cells Inhibits Tumor Growth in Bone and Mammary Fat Pad. PloS ONE 7(1):e30255, 2012. PMID: 22276166.
45. He Y, Rhodes SD, Chen S, Wu X, Yuan J, Yang X, Jiang L, Li X, Takahashi N, Xu M, Mohammad KS, Guise TA, Yang FC. c-Fms Signaling Mediates Neurofibromatosis Type-1 Osteoclast Gain-In-Functions. PloS ONE 7(11):e46900, 2012. PMID: 23144792.
46. Buijs JT, Juarez P, Guise TA. Therapeutic Strategies to Target TGFß in the Treatment of Bone Metastases. Curr Pharm Biotechnol 12(12):2121-2137, 2011. PMID: 21619539.
47. Hadji P, Aapro MS, Body JJ, Bundred NJ, Brufsky A, Coleman RE, Gnant M, Guise T, Lipton A. Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment. Ann Oncol 22(12):2546-2555, 2011. PMID: 21415233.
48. Clines GA, Mohammad KS, Grunda JM, Clines KL, Niewolna M, McKenna CR, McKibbin CR, Yanagisawa M, Suva LJ, Chirgwin JM, Guise TA. Regulation of postnatal trabecular bone formation by the osteoblast endothelin A receptor. J Bone Miner Res 26(10):2523-2536, 2011. PMID: 21698666.
49. Weilbaecher, K, Guise TA, McCauley LM. Cancer to bone: the fatal attraction. Nature Reviews Cancer 11(6):411-425, 2011. PMID: 21593787.
50. Liang H, Ma SY, Mohammad K, Guise TA, Balian G, Shen FH. The reaction of bone to tumor growth from human breast cancer cells in a rat spine single metastasis model. Spine 36(7):497-504, 2011. PMID: 21422981.
51. Edwards BJ, Raisch DW, Shankaran V, McKoy JM, Gradishar W, Bunta AD, Samaras AT, Boyle SN, Bennett CL, West DP, Guise TA. Cancer therapy associated bone loss: implications for hip fractures in mid-life women with breast cancer. Clin Cancer Res 17(3):560-568, 2011. PMID: 21288927.
52. Wu X, Chen S, He Y, Rhodes SD, Mohammad KS, Li X, Yang X, Jiang L, Nalepa G, Snider P, Robling AG, Clapp DW, Conway SJ, <b>Guise TA</b>, Yang FC. The haploinsufficient hematopoietic microenvironment is critical to the pathological fracture repair in murine models of neurofibromatosis type 1. PloS ONE 6(9):e24917, 2011. PMID: 21980365.
53. Guise TA, Brufsky A, Coleman RE. Understanding and optimizing bone health in breast cancer. Curr Med Res Opin 26(Suppl 3):3-20, 2010. PMID: 21050131.
54. Hu Z, Zhang Z, Guise T, Seth P. Systemic Delivery of an Oncolytic Adenovirus Expressing Soluble TGFß Receptor II-Fc Fusion Protein Can Inhibit Breast Cancer Bone Metastasis in a Mouse Model. Hum Gene Ther 21(11):1623-1629, 2010. PMID: 20712434.
55. Mohammad KS, Javelaud D, Fournier PG, Niewolna M, McKenna CR, Peng XH, Duong V, Dunn LK, Mauviel A, Guise TA. The Transforming Growth Factor-{beta} Receptor I Kinase Inhibitor SD-208 Reduces the Development and Progression of Melanoma Bone Metastases. Cancer Res 71(1):175-184, 2010. PMID: 21084275.
56. Guise,TA. Examining the metastatic niche: targeting the microenvironment. Semin Oncol 37(Suppl 2):S2-14, 2010. PMID: 21111245.
57. Alexaki VI, Javelaud, D, Van Kempen LCL, Mohammad KS, Dennler S, Luciani F, Hoek K, Juarez P, Goydos JS, Sibon C, Bertolotto C, Verrecchia F, Saule S, Delmas V, Ballotti R, Larue L, Saiag P, Guise, TA, Mauviel A. GLI2, A TGF-ß-inducible target, promotes melanoma invasion and metastasis. J Natl Cancer Inst 102(15):1148-1159, 2010. PMID: 20660365.
58. Coenegrachts L, Maes C, Torrekens S, Van Looveren R, Mazzone M, Guise TA, Bouillon R, Stassen JM, Carmeliet P, Carmeliet G. Anti-placental growth factor reduces bone metastasis by blocking tumor cell engraftment and osteoclast differentiation. Cancer Res 70(16):6537-6547, 2010. PMID: 20682798.
59. Juarez,P, Guise,TA. TGFß in cancer and bone: Implications for treatment of bone metastases. Bone 48(1):23-29, 2010. PMID: 20699127.
60. Coleman RE, Lipton A, Roodman GD, Guise TA, Boyce BF, Brufsky AM, Clezardin P, Croucher PI, Gralow JR, Hadji P, Holen I, Mundy GR, Smith MR, Suva LJ. Metastasis and bone loss: Advancing treatment and prevention. Cancer Treat Rev 36(8):612-620, 2010. PMID: 20478658.
61. Pollari S, Kakonen SM, Edgren H, Wolf M, Kohonen P, Sara H, Guise T, Nees M, Kallioniemi O. Enhanced serine production by bone metastatic breast cancer cells stimulate osteoclastogenesis. Breast Cancer Res Treat 125(2):421-430, 2010. PMID: 20352489.
62. Akech J, Wixted JJ, Bedard K, van der Deen M, Hussain S, Guise TA, van Wijnen AJ, Stein JL, Languino LR, Altieri DC, Pratap J, Keller E, Stein GS, Lian JB. Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions. Oncogene 29(6):811-821, 2009. PMID: 19915614.
63. Casimiro S, Guise TA, Chirgwin J. The critical role of the bone microenvironment in cancer metastases. Mol Cell Endocrinol 310(1-2):71-81, 2009. PMID: 19616059.
64. Hu Z, Robbins JS, Pister A, Zafar MB, Zhang ZW, Gupta J, Lee KJ, Neuman K, Yun CO, Guise T, Seth P. A modified hTERT promoter-directed oncolytic adenovirus replication with concurrent inhibition of TGFß signaling for breast cancer therapy. Cancer Gene Ther 17(4):235-243, 2009. PMID: 19798122.
65. Dunn LK, Mohammad KS, Fournier PGJ,, McKenna CR, Davis HW, Niewolna M, Peng XP, Chirgwin JM, Guise TA. Hypoxia and TGF-β Drive Breast Cancer Bone Metastases through Parallel Signaling Pathways in Tumor Cells and the Bone Microenvironment. PloS ONE 4(9):e6896, 2009. PMID: 19727403.
66. Brown,SA, Guise,TA. Cancer treatment-related bone disease. Crit Rev Eukaryot Gen Expr 19(1):47-60, 2009. PMID: 19191756.
67. Guise TA, O’Keefe R, Randall L, Terek RM. Molecular biology and therapeutics in musculoskeletal oncology. J Bone Joint Surg Am 91:724-732, 2009. PMID: 19255238.
68. Mohammad KS, Chen C, Balooch G, Stebbins E, McKenna CR, Walton H, Niewolna M, Peng X, Nguyen D, Ionova-Martin SS, Bracey JW, Hogue WR, Wong DH, Ritchie RO, Suva LJ, Derynck R, Guise TA, Alliston T. Pharmacologic inhibition of the TGF-β type 1 receptor kinase has anabolic and anti-catabolic effects on bone. PloS ONE 4(4):e5275, 2009. PMID: 19357790.
69. Coleman RE, Guise TA, Lipton A, Roodman GD, Berenson JR, Body JJ, Boyce BF, Calvi LM, Hadji P, McCloskey EV, Saad F, Smith MR, Suva LJ, Taichman RS, Vessella RL, Weilbaecher KN. Advancing treatment for metastatic bone cancer: consensus recommendations from the Second Cambridge Conference. Clin Cancer Res 14(20):6387-6395, 2008. PMID: 18927277.
70. American Society for Bone and Mineral Research Task Force on Osteonecrosis of the Jaw, Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, Gagel RF, Gilsanz V, Guise T, Koka S, McCauley LK, McGowan J, McKee MD, Mohla S, Pendrys DG, Raisz LG, Ruggiero SL, Shafer DM, Shum L, Silverman SL, Van Poznak CH, Watts N, Woo SB, Shane E. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 66(6):1320-1321, 2008. PMID: 18486811.
71. Hadji P, Body JJ, Aapro MS, Brufsky A, Coleman RE, Guise T, Lipton A, Tubiana-Hulin M. Practical guidance for the management of aromatase inhibitor-associated bone loss. Ann Oncol 19(8):1407-1416, 2008. PMID: 18448451.
72. Clines GA, Guise TA. Molecular mechanisms and treatment of bone metastasis. Expert Rev Mol Med 10(e7), 2008. PMID: 18321396.
73. Akhtari M, Mansuri J, Newman KA, Guise T, Seth P. Biology of breast cancer bone metastasis. Cancer Biol Ther 7(1):3-9, 2008. PMID: 18059174.
74. Brown SA, Clines GA, Guise TA. Local effects of malignancy on bone. Curr Opin Endocrinol Diabetes Obes 14(6):3-9, 2007. PMID: 17982348.
75. Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, Gagel RF, Gilsanz V, Guise T, Koka S, McCauley LK, McGowan J, McKee MD, Mohla S, Pendrys, DG, Raisz LG, Ruggiero SL, Shafer DM, Shum L, Silverman SL, Van Poznak CH, Watts N, Woo SB, Shane E. Bisphosphonate-associated osteonecrosis of the jaw: Report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 22(10):1479-1491, 2007. PMID: 17663640.
76. Kingsley LA, Fournier PG, Chirgwin JM, Guise TA. Molecular biology of bone metastasis. Mol Cancer Ther 6(10):2609-2617, 2007. PMID: 17938257.
77. Guise TA, Oefelein MG, Eastham JA, Cookson MS, Higano CS, Smith MR. Estrogenic side effects of androgen deprivation therapy. Rev Urol 9(4):163-180, 2007. PMID: 18231613.
78. Fournier PGJ, Guise TA. BMP7: A New Bone Metastases Prevention?. Am J Pathol 171(3):739-743, 2007. PMID: 17690188.
79. Brown,SA, Guise,TA. Cancer-associated bone disease. Curr Osteoporos Rep 5(3):120-127, 2007. PMID: 17925193.
80. Brown SA, Guise TA. Drug insight: the use of bisphosphonates for the prevention and treatment of osteoporosis in men. Nat Clin Pract Urol 4(6):310-320, 2007. PMID: 17551535.
81. Kingsley LA, Chirgwin JM, Guise TA. Breaking new ground to build bone. Proc Natl Acad Sci USA 104(26):10753-10754, 2007. PMID: 17581868.
82. Javelaud D, Mohammad KS, McKenna CR, Fournier P, Luciani F, Niewolna M, André J, Delmas V, Larue L, Guise TA, Mauviel A. Stable overexpression of Smad7 in human melanoma cells impairs bone metastasis. Cancer Res 67(5):2317-2324, 2007. PMID: 17332363.
83. Bartholin L, Wessner L, Chirgwin JM, Guise, TA. The human Cyr61 gene is a transcriptional target of transforming growth factor ß. Cancer Lett 246(1-2):230-236, 2007. PMID: 16616811.
84. Clines GA, Mohammad KS, Bao Y, Stephens OW, Suva LJ, Shaughnessy JD Jr, Fox JW, Chirgwin JM, Guise TA. Dickkopf homolog 1 mediates endothelin-1-stimulated new bone formation. Mol Endocrinol 21(2):486-498, 2007. PMID: 17068196.
85. Seth P, Wang ZG, Pister A, Zafar MB, Kim S, Guise T, Wakefield L. Development of oncolytic adenovirus armed with a fusion of soluble transforming growth factor-beta receptor II and human immunoglobulin Fc for breast cancer therapy. Hum Gene Ther 17(11):1152-1160, 2006. PMID: 17032151.
86. Guise,TA. Bone loss and fracture risk associated with cancer therapy. Oncologist 11(10):1121-1131, 2006. PMID: 17110632.
87. Guise TA, Mohammad KS, Clines G, Stebbins EG, Wong DH, Higgins LS, Vessella R, Corey E, Padalecki S, Suva L, Chirgwin JM. Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin Cancer Res 12(20):6213s-6216s, 2006. PMID: 17062703.
88. Lipton A, Berenson JR, Body JJ, Boyce BF, Bruland OS, Carducci MA, Cleeland CS, Clohisy DR, Coleman RE, Cook RJ, Guise TA, Pearse RN, Powles TJ, Rogers MJ, Roodman GD, Smith MR, Suva LJ, Vessella RL, Weilbaecher KN, King L. Advances in treating metastatic bone cancer: Summary statement for the First Cambridge Conference. Clin Cancer Res 12(20):6209s-6212s, 2006. PMID: 17062702.
89. Guise,TA. Do markers of bone turnover predict clinical outcome in patients with bone metastases?. Nat Clin Pract Endocrinol Metab 2(5):258-259, 2006. PMID: 16932296.
90. Theriault RL, Biermann JS, Brown E, Brufsky A, Demers L, Grewal RK, Guise T, Jackson R, McEnery K, Podoloff D, Ravdin P, Shapiro CL, Smith M, Van Poznak CH. NCCN Task Force Report: Bone health and cancer care. J Natl Compr Canc Netw 4 Suppl(2):S1-20, 2006. PMID: 16737674.
91. Zudaire E, Martinez A, Garayoa M, Pio R, Kaur G, Woolhiser MR, Metcalfe DD, Hook WA, Siraganian RP, Guise TA, Chirgwin JM, Cuttitta F. Adrenomedullin is a cross-talk molecule that regulates tumor and mast cell function during human carcinogenesis. Am J Pathol 168(1):280-291, 2006. PMID: 16400030.
92. Bendre,MS, Margulies,AG, Walser,B, Akel,NS, Bhattacharrya,S, Skinner,RA, Swain,F, Ramani,V, Mohammad,KS, Wassner,LL, Martinez,A, Guise,TA, Chirgwin,JM, Gaddy,D, Suva,LJ. Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-kappaB ligand pathway. Cancer Res 65(23):11001-11009, 2005. PMID: 16322249.
93. Clines,GA, Guise,TA. Hypercalcaemai of malignancy and basic research on mechanisms responsible for osteolytic and osteoblastic metastasis to bone. Endocr Relat Cancer 12(3):549-583, 2005. PMID: 16172192.
94. Titus B, Frierson HF Jr, Conaway M, Ching K, Guise T, Chirgwin J, Hampton G, Theodorescu D. Endothelin axis is a target of the lung metastasis suppressor gene RhoGDI2. Cancer Res 65(16):7320-7327, 2005. PMID: 16103083.
95. Kozlow W, Guise TA. Breast cancer metastasis to bone: mechanisms of osteolysis and implications for therapy. J Mammary Gland Biol Neoplasia 10(2):169-180, 2005. PMID: 16025223.
96. Aris RM, Merkel PA, Bachrach LK, Borowitz DS, Boyle MP, Elkin SL, Guise TA, Hardin DS, Haworth CS, Holick MF, Joseph PM, O’Brien K, Tullis E, Watts NB, White TB.. Consensus Conference Report: Guide to bone health and disease in cystic fibrosis. J Clin Endocrinol Metab 80(3):1888-1896, 2005. PMID: 15613415.
97. Chirgwin,JM, Mohammad,KS, Guise,TA. Tumor-bone cellular interactions in skeletal metastases. J Musculoskelet Neuronal Interact 4(3):308-318, 2004. PMID: 15615499.
98. Diamond TH, Higano CS, Smith MR, Guise TA, Singer FR. Osteoporosis in men with prostate cancer receiving androgen deprivation therapy: recommendations for diagnosis and therapies. Cancer 100(5):892-899, 2004. PMID: 14983482.
99. Maier B, Gluba W, Bernier B, Turner T, Mohammad K, Guise TA, Sutherland A, Thorner M, Scrable H. Modulation of mammalian life-span by the short isoform of p53. Genes Dev 18(3):306-319, 2004. PMID: 14871929.
100. Guise TA, Chirgwin JM. Role of bisphosphonates in prostate cancer bone metastases. Sem Oncol 30(5):717-723, 2003. PMID: 14571419.
101. Mohammad KS, Guise TA. Mechanisms of osteoblastic metastases: role of endothelin-1. Clinical Orthop Relat Res (415 Suppl):S67-74, 2003. PMID: 14600594.
102. Guise TA, Chirgwin JM. Transforming growth factor beta in osteolytic breast cancer bone metastases. Clinical Orthop Relat Res (415 Suppl):S32-38, 2003. PMID: 14600590.
103. O’Keefe RJ, Guise TA. Molecular mechanisms of bone metastasis and therapeutic implications. Clinical Orthop Relat Res (415 Suppl):S100-104, 2003. PMID: 14600598.
104. Weissman BE, Dallas M, Guise TA, Leach RJ, Johnson-Pais, T. Chromosome 18 suppresses prostate cancer metastases. Urol Oncol 21(5):366-373, 2003. PMID: 14670546.
105. Yin JJ, Mohammad KS, Käkönen SM, Harris S, Wu-Wong JR, Wessale J, Padley R, Garrett IR, Chirgwin JM, Guise TA. A causal role for endothelin-1 in the pathogenesis of osteoblastic metastases. Proc natl Acad Sci USA 100(19):1054-1059, 2003. PMID: 12941866.
106. Kang Y, Siegel PM, Shu WP, Drobnjak M, Käkönen SM, Cordon-Cardo C, Guise TA, Massagué J. A multigenic program mediating breast cancer metastases to bone. Cancer Cell 3(6):537-549, 2003. PMID: 12842083.
107. Lindemann RK, Braig M, Ballschmieter P, Guise TA, Nordheim A, Dittmer J.. Protein kinase Ca regulates Ets1 transcriptional activity in invasive breast cancer cells. Int J Oncol 22(4):799-805, 2003. PMID: 12632071.
108. Kos C, Karaplis A, Goltzman D, Mohammad K, Guise, TA, Pollack M. The calcium-sensing receptor is required for normal calcium homeostatis independent of parathyroid hormone. J Clin Invest 111(7):1021-1028, 2003. PMID: 12671051.
109. Guise TA, Yin JJ, Mohammad K. Role of endothelin-1 in osteoblastic bone metastases. Cancer 97(3 (Suppl)):779-784, 2003. PMID: 12548575.
110. Gallwitz WE, Guise,TA, Mundy,GR. Guanosine nucleotides inhibit the development of osteolytic bone disease due to metastatic breast cancer by their capacity to decrease PTHrP expression. J Clin Invest 110(10):1559-1572, 2002. PMID: 12438453.
111. Guise,TA, Yin,JJ, Thomas,RJ, Dallas,M, Bui,Y, Gillespie,MT. Parathyroid hormone-related protein (PTHrP)-(1-139) isoform is efficiently secreted in vitro and enhances breast cancer metastasis to bone in vivo. Bone 30(5):670-676, 2002. PMID: 11996903.
112. Wysolmerski,JJ, Dann,PR, Zelazny,E, Dunbar,MR, Insogna,KL, Guise,TA, Perkins,AS. Overexpression of parathyroid hormone-related protein causes hypercalcemia but not bone metastases in a murine model of mammary tumorigenesis. J Bone Miner Res 17(7):1167-1170, 2002. PMID: 12096830.
113. KaKonen,SM, Selander,KS, Chirgwin,JM, Yin,JJ, Burns,S, Rankin,WA, Grubbs,BG, Dallas,M, Cui,Y, Guise,TA. Transforming growth factorß stimulates parathyroid hormone-related protein and osteolytic metastases via Smad and mitogen-activated protein kinase signaling pathways. Biol Chem 277(27):24571-24578, 2002. PMID: 11964407.
114. Padalecki,SS, Guise,TA. Actions of bisphosphonates in animal models of breast cancer. Breast Cancer Res 4(1):35-41, 2001. PMID: 11879558.
115. Chirgwin,JM, Guise,TA. Molecular mechanisms of tumor-bone interactions in osteolytic metastases. Crit Rev Eukaryot Gene Expr 10(2):159-178, 2000. PMID: 11186331.
116. Vargas,GE, Uy,H, Bazan,C, Guise,TA, Bruder,JM. Hemiplegia after thryrotropin alfa in a hypothyroid patient with thyroid carcinoma metastatic to the brain. J Clin Endocrinol Metab 84(11):3867-3871, 1999. PMID: 10566621.
117. Thomas,RJ, Guise,TA, Yin,JJ, Elliott,J, Horwood,NJ, Martin, TJ, Gillespie,MT. Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinol 140(10):4451-4458, 1999. PMID: 10499498.
118. Boyce, BF, Yoneda,T, Guise,TA. Factors regulating the growth of metastatic cancer in bone. Endocr Relat Cancer 6(3):333-347, 1999. PMID: 10516850.
119. Lemieux, PM, Guise,TA, Dallas,M, Oesterreich,S, Yin,JJ, Selander,K, Fuqua,SAW. Low cell motility induced by Hsp27 overexpression decreased osteolytic metastases formation by human breast cancer cells in vivo. J Bone Miner Res 14(9):1570-1575, 1999. PMID: 10469286.
120. Yin,JJ, Selander,KL, Chirgwin, JM, Dallas,M, Grubbs,BG, Wieser,R, Massaque,J, Mundy,GR, Guise,TA. TGFß signaling blockade inhibits parathyroid hormone-related protein secretion by breast cancer cells and bone metastases development. J Clin Invest 103(2):197-206, 1999. PMID: 9916131.
121. Guise TA, Mundy GR.. Cancer and Bone. Endocr Rev 19(1):18-54, 1998. PMID: 9494779.
122. Mundy GR, Guise TA. Hypercalcemia of Malignancy. Am J Med 103(2):134-145, 1997. PMID: 9274897.
123. Uy HL, Mundy GR, Boyce BF, Story BM, Dunstan CR, Yin JJ, Roodman GD, Guise TA. Tumor necrosis factor enhances parathyroid hormone-related protein (PTHrP)-induced hypercalcemia and bone resorption without inhibiting bone formation in vivo. Cancer Res 57(15):3194-3199, 1997. PMID: 9242449.
124. Guise TA, Yin JJ, Taylor SD, Kumagai Y, Dallas M, Boyce BF, Yoneda T, Mundy GR. Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest 98(7):1544-1549, 1996. PMID: 8833902.
125. Wysolmerski JJ, Vasavada R, Foley J, Weir EC, Burtis WJ, Kukreja SC, Guise TA, Broadus AE, Philbrick WM. Transactivation of the PTHrP gene in squamous carcinomas predicts the occurrence of hypercalcemia in athymic mice. Cancer Res 56(5):1043-1049, 1996. PMID: 8640759.
126. Uy HL, Guise TA, De La Mata J, Taylor SD, Story BM, Dallas MR, Boyce BF, Mundy GR, Roodman GD.. Effects of parathyroid hormone (PTH)-related protein and PTH on osteoclasts and osteoclast precursors in vivo. Endocrinol 136(8):3207-3212, 1995. PMID: 7628353.
127. Guise TA, Mundy GR.. Clinical review 69: Evaluation of hypocalcemia in children and adults. Clin Endocrinol Metab 80(5):1473-1478, 1995. PMID: 7744987.
128. DeLaMata J, Uy HL, Guise TA, Story B, Boyce BF, Mundy GR, Roodman GD. Interleukin-6 enhances hypercalcemia and bone resorption mediated by PTH-rP in vivo. J Clin Invest 95(6):2846-2852, 1995. PMID: 7769125.
129. Guise TA, Yoneda T, Yates AJP, Mundy GR. The combined effect of tumor-produced parathyroid hormone-related peptide and transforming growth factor a enhance hypercalcemia in vivo and bone resorption in vitro. J Clin Endocrinol Metab 77(1):40-45, 1993. PMID: 8325957.
130. Garrett IR, Guise TA, Bonewald LF, Chizzonite R, Mundy GR. Evidence that interleukin-1 mediates its effects on bone resorption via the 80 kilodalton interleukin-1 receptor. Calcif Tissue Inter 52(6):438-441, 1993. PMID: 8369991.
131. Guise TA, Garrett IR, Bonewald LF, Mundy GR. Interleukin-1 receptor antagonist inhibits hypercalcemia mediated by interleukin-1. J Bone Miner Res 8(5):583-587, 1993. PMID: 8511985.
132. Guise TA, Chirgwin JM, Favarato G, Boyce BF, Mundy GR. Chinese hamster ovarian cells transfected with human parathyroid hormone-related protein cDNA cause hypercalcemia in nude mice. Lab Invest 67(4):477-485, 1992. PMID: 1434529.

Invited Articles

1. Waning DL, Guise TA, Mohammad KS. A "Connexin" Responsible for the Fatal Attraction of Cancer to Bone. Cell Metab 29(1):6-8, 2019. PMID: 30625309.
2. Heinrich D, Bruland Ø, Guise TA, Suzuki H, Sartor O. Alkaline phosphatase in metastatic castration-resistant prostate cancer: reassessment of an older biomarker. Future Oncol 14(24):2543-2556, 2018. PMID: 29925281.
3. Esposito M, Guise T, Kang Y. The Biology of Bone Metastasis. Cold Spring Harb Perspect Med 8(6):a031252, 2018. PMID: 29101110.
4. Mohammad KS, Guise TA. Breaking Down Barriers to Chemoresistance: Role of Chemotherapy-Induced Osteoblastic Jagged1. Cancer Cell 32(6):717-718, 2017. PMID: 29232546.
5. Regan JN, Trivedi T, Guise TA, Waning DL. The Role of TGFβ in Bone-Muscle Crosstalk. Curr Osteoporos Rep 15(12):18-23, 2017. PMID: 28161871.
6. Mohammad KS, Guise TA. Hypercalcemia of Malignancy: A New Twist on an Old Problem. Oncol Pract 12(5):435-436, 2016. PMID: 27170692.
7. Regan JN, Waning DL, Guise TA. Skeletal muscle Ca(2+) mishandling: Another effect of bone-to-muscle signaling. Semin Cell Dev Biol(49):24-29, 2016. PMID: 26593325.
8. Waning DL, Guise TA. Cancer-associated muscle weakness: What's bone got to do with it?. Bonekey Rep(4):691, 2015. PMID: 25992285.
9. Wright LE, Guise TA. The microenvironment matters: estrogen deficiency fuels cancer bone metastases. Clin Cancer Res 20(11):2817-2819, 2014. PMID: 24803577.
10. Waning DL, Mohammad KS, Guise TA. Cancer-associated osteoclast differentiation takes a good look in the miR(NA)ror. Cancer Cell 24(4):407-409, 2013. PMID: 24135278.
11. Chiechi A, Waning DL, Stayrook KR, Buijs JT, Guise TA, Mohammad KS. Role of TGF- β in breast cancer bone metastases. Adv Biosci Biotechnol 4(10C):15-30, 2013. PMID: 24558636.
12. Guise,TA. Breast cancer bone metastases: it's all about the neighborhood. Cell 154(5):957-959, 2013. PMID: 23993088.
13. Juarez P, Guise TA. Tgf-Beta pathway as a therapeutic target in bone metastases. Curr Pharm Des 16(11):1301-1312, 2010. PMID: 20166877.
14. Mohammad KS, Chirgwin JM, Guise TA. Assessing new bone formation in neonatal calvarial organ cultures. Methods Mol Biol 455:37-50, 2008. PMID: 18463809.
15. Siclari VA, Guise TA, Chirgwin JM. Molecular interactions between breast cancer cells and the bone microenvironment drive skeletal metastases. Cancer Metastasis Rev 25(4):621-633, 2006. PMID: 17165131.
16. Fournier P, Chirgwin JM, Guise TA. New insights into the role of T cells in the vicious cycle of bone metastases. Curr Opin Rheumatol 18(4):396-404, 2006. PMID: 16763461.
17. Guise TA, Kozlow WM, Heras-Herzig A, Padalecki SS, Yin JJ, Chirgwin JM. Molecular mechanisms of breast cancer metastases to bone. Clin Breast Cancer 5(Suppl 2):S46-53, 2005. PMID: 15807924.
18. Aris RM, Guise TA. Cystic fibrosis and bone disease: are we missing a genetic link?. Eur Respir J 25(1):9-11, 2005. PMID: 15640316.
19. Clines GA, Guise TA. Mechanisms and treatment for bone metastases. Clin Adv Hematol Oncol 2(5):295-301, 2004. PMID: 16163196.
20. Guise TA, Mohammad KS. Endothelins in bone cancer metastases. Cancer Treat Res 118:197-212, 2004. PMID: 15043194.
21. Heras-Herzig A, Guise TA. Effects of drug treatment for malignancy on skeletal health of cancer survivors. Clin Rev Bone Miner Metab 2(2):103-114, 2004.
22. Guise TA, Mohammad KS, Käkönen SM, Chirgwin JM. Molecular mechanisms of bone metastases. American Society of Clinical Oncology Educational Book from 39th Annual Meeting:77-80, 2003.
23. Chirgwin JM, Guise TA. Cancer metastases to bone. Science and Medicine 9:140-151, 2003.
24. Guise,TA. How metastases home to bone: The attraction of chemokines. IBMS BoneKEy, 2002.
25. Guise,TA. Running with Grave’s disease. American Running Association Running & Fitness 20(3):7, 2002.
26. Guise,TA. The vicious cycle of bone metastases. Journal of Musculoskeletal Neuron Interactions 2(6):570-572, 2002. PMID: 15758398.
27. Guise,TA. From chondrocytes to cancer: Fibroblast growth factor receptor 3 (FGFR3). Commentary in IBMS BoneKEy, 2001.
28. Guise,TA. Molecular mechanisms of osteolytic metastases. Cancer 88((12 Suppl)):2892-2898, 2000. PMID: 10898330.
29. Mundy GR, Guise TA. Hormonal control of calcium homeostasis. Clin Chem 45(8):1347-1352, 1999. PMID: 10430817.
30. Boyce BF, Yoneda T, Guise TA. Molecular Basis of Bone Disease, Bone disease in malignancy. Advances in Organ Biology: Molecular and Cell Biology of Bone 5C(IV):709-738, 1998.
31. Mundy GR, Guise TA. Role of parathyroid hormone-related protein in hypercalcemia of malignancy and osteolytic bone disease. Endocrine-Related Cancer 5:15-26, 1998.
32. Guise,TA. Parathyroid hormone-related protein (PTHrP) and bone metastases. Cancer 80:1572-1580, 1997. PMID: 9362424.
33. Guise,TA. Running “contact.”. Runner's World 32(5):17, 1997.
34. Guise TA, Mundy GR.. Physiological and pathological roles of parathyroid hormone-related peptide. Curr Opin Nephrol Hypertens 5(4):307-315, 1996. PMID: 8823527.
35. Alsina M, Guise TA, Roodman GD. Cytokine regulation of bone cell differentiation. Vitam Horm 52:63-98, 1996. PMID: 8909157.
36. Guise TA, Mundy GR.. Breast cancer and bone. Curr Opin Endocrinol Diabetes Parathyroids and Bone and Mineral Metabolism(2):465-467, 1995.
37. Guise,TA. Development of bone metastases and tumour osteolysis. Canadian J Diagnosis(Supplement):16-20, 1993.

Book Chapters

1. Clines GA, Guise TA. Mechanisms of bone destruction and bone formation by metastatic tumors. In: Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. Sixth. American Society for Bone and Mineral Research, 2006.
2. Guise TA, Chirgwin JM. Biology of bone metastases. In: Diseases of the Breast. Third. Lippman, Morrow and Osborne: Philadelphia, 1285-1296, 2004.
3. Mohammad KS, Guise TA. Osteoblastic bone metastases. In: Bone Metastases. First. Chung, 2004.
4. Clines GA, Guise TA. Hypercalcaemia in hematologic malignancies and in solid tumors associated with extensive localized bone destruction. In: Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. Fifth. American Society for Bone and Mineral Research, 251-253, 2003.
5. Mundy GR, Yoneda T, Guise TA, Oyajobi B. Local factors in skeletal malignancy. In: Principles of Bone Biology. Second. Academic Press, 1093-1104, 2002.
6. Guise,TA. Therapy affecting bone resorption and deposition. In: Management of Metastatic Disease to the Musculoskeletal System. Quality Medical Publishing, 107-138, 2002.
7. Bruder JA, Guise TA, Mundy GR. Disorders of calcium metabolism. In: Endocrinology and Metabolism. Fourth. McGraw Hill Book Company, 1079-1159, 2001.
8. Guise TA, Mundy GR.. Disorders of calcium homeostasis. In: The Kidney: Physiology and Pathophysiology. Third. Lippincott, Williams & wilkins: Philadelphia, 1811-1839, 2000.
9. Mundy GR, Guise TA. Pathophysiology of bone metastasis. In: Cancer and the Skeleton. Martin Dunitz Ltd, 43-64, 2000.
10. 11. Mundy GR, Yoneda T, Guise TA. Hypercalcaemia in hematologic malignancies and in solid tumors associated with extensive localized bone destruction. In: Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. Fourth. Lippincott Williams & Wilkins, 208-212, 1999.
11. Mundy GR, Guise TA. Biology of bone metastases. In: Diseases of the Breast. Second. Lippman, Morrow and Osborne, 911-920, 1999.
12. Guise TA, Mundy GR.. Disorders of calcium metabolism. In: Therapy of Renal Diseases and Related Disorders. 3rd. Kluwer Academic Publishers, 85-114, 1997.